Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for Pure Class V Lupus Nephritis (OBLUMEN)
NCT07721363Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in lupus nephritis (LN) and membranous nephropathy (MN), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete Renal Response at 52 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT07721363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721363.